Skip to main content

Articles

Page 1 of 2

  1. Endometrial stromal sarcoma (ESS) is a rare neoplasm accounting for only 0.2% of female genital tract tumors. The primary extra-uterine location of ESS is an extremely uncommon occurrence.

    Authors: Boubacar Efared, Ibrahim S. Sidibé, Fatimazahra Erregad, Nawal Hammas, Laila Chbani and Hinde El Fatemi
    Citation: Gynecologic Oncology Research and Practice 2019 6:2
  2. Although genetic testing is recommended for women with epithelial ovarian cancer (EOC), little is known about patient preferences for various testing options. We measured relative preferences for attributes of...

    Authors: Brittany A. Davidson, Jessie Ehrisman, Shelby D. Reed, Jui-Chen Yang, Adam Buchanan and Laura J. Havrilesky
    Citation: Gynecologic Oncology Research and Practice 2019 6:1
  3. Widespread concerns have been raised regarding the safety of power morcellation of uterine specimens because of the potential to disseminate occult malignancy. We sought to assess the safety and feasibility of...

    Authors: Sarah Dotson, Alejandro Landa, Jessie Ehrisman and Angeles Alvarez Secord
    Citation: Gynecologic Oncology Research and Practice 2018 5:8
  4. Ovarian cancer remains a major health problem for women as it is often diagnosed at a late stage with metastatic disease. There are limited therapeutic agents and survival rates remain poor. The perinucleolar ...

    Authors: Margaux J. Kanis, Wenan Qiang, Mario Pineda, Kruti P. Maniar and J. Julie Kim
    Citation: Gynecologic Oncology Research and Practice 2018 5:7
  5. Ovarian carcinosarcoma is a rare malignancy associated with a high rate of cancer-related mortality even at early stages. Guidelines for systemic treatment have been difficult to establish because the disease ...

    Authors: Graziela Zibetti Dal Molin, Carina Meira Abrahão, Robert L. Coleman and Fernando Cotait Maluf
    Citation: Gynecologic Oncology Research and Practice 2018 5:6
  6. In India, cervical cancer accounts for almost 14% of all female cancer cases. Although poverty continues to cast a wide net over the Indian subcontinent, the preceding three decades have borne witness to impro...

    Authors: K. S. Tewari, A. Agarwal, A. Pathak, A. Ramesh, B. Parikh, M. Singhal, G. Saini, P. V. Sushma, N. Huilgol, S. Gundeti, S. Gupta, S. Nangia, S. Rawat, S. Alurkar, V. Goswami, B. Swarup…
    Citation: Gynecologic Oncology Research and Practice 2018 5:5
  7. Measuring QoL is essential to the field of gynecologic oncology but there seems to be limited standardized data regarding collecting QoL assessments throughout a patient’s cancer treatment especially in non-cl...

    Authors: D. Barnes, R. Rivera, S. Gibson, C. Craig, J. Cragun, B. Monk and D. Chase
    Citation: Gynecologic Oncology Research and Practice 2018 5:4
  8. The burden of HIV and cervical cancer is concentrated in sub-Saharan Africa. Women with HIV are more likely to have persistent HPV infection leading to cervical abnormalities and cancer. Cervical cancer screen...

    Authors: Nancy Innocentia Ebu
    Citation: Gynecologic Oncology Research and Practice 2018 5:3
  9. Gynaecological cancers may be the sentinel malignancy in women who carry a mutation in BRCA1 or 2, a mis-match repair gene causing Lynch Syndrome or other genes. Despite published guidelines for referral to a ...

    Authors: Hanoon P. Pokharel, Neville F. Hacker and Lesley Andrews
    Citation: Gynecologic Oncology Research and Practice 2018 5:2
  10. Combretastatin A4-phosphate (CA4P) is a vascular-disrupting agent (VDA) in clinical development for the treatment of ovarian and other cancers. In contrast to antiangiogenic agents, such as bevacizumab, which ...

    Authors: Rachel Grisham, Bonnie Ky, Krishnansu S. Tewari, David J. Chaplin and Joan Walker
    Citation: Gynecologic Oncology Research and Practice 2018 5:1
  11. In Ethiopia, cervical cancer is ranked as the second most common type of cancer in women and it is about 8 times more common in HIV infected women. However, data on knowledge of HIV infected women regarding ce...

    Authors: Daniel Asfaw Erku, Adeladlew Kassie Netere, Amanual Getnet Mersha, Sileshi Ayele Abebe, Abebe Basazn Mekuria and Sewunet Admasu Belachew
    Citation: Gynecologic Oncology Research and Practice 2017 4:20
  12. Endometrial cancer is the most common gynecologic malignancy in the United States, accounting for 6% of cancers in women. In 2017, an estimated 61,380 women were diagnosed with endometrial cancer, and approxim...

    Authors: Vicky Makker, Angela K. Green, Robert M. Wenham, David Mutch, Brittany Davidson and David Scott Miller
    Citation: Gynecologic Oncology Research and Practice 2017 4:19
  13. Poly (ADP-ribose) polymerases (PARPs) are an important family of nucleoproteins highly implicated in DNA damage repair. Among the PARP families, the most studied are PARP1, PARP2 and PARP 3. PARP1 is found to ...

    Authors: Mekonnen Sisay and Dumessa Edessa
    Citation: Gynecologic Oncology Research and Practice 2017 4:18
  14. While many of these agents have been compared in prospective clinical trials, the gemcitabine/platinumbased regimens have not been compared in a prospective, randomized clinical trial. While bothgemcitabine/ca...

    Authors: Tran N. Le, Rachel E. Harvey, Christine K. Kim, Jubilee Brown, Robert L. Coleman and Judith A. Smith
    Citation: Gynecologic Oncology Research and Practice 2017 4:16
  15. Clear cell carcinoma and endometrioid adenocarcinoma are histologic subtypes of ovarian and uterine cancer that demonstrate unique clinical behavior but share common underlying genomic aberrations and oncogeni...

    Authors: Jill K. Alldredge and Ramez N. Eskander
    Citation: Gynecologic Oncology Research and Practice 2017 4:17
  16. Although cervical cancer is preventable, it is still the second leading cause of cancer deaths among women in the world. Further, it is estimated that around 5–10% of hospital admissions are due to drug relate...

    Authors: Amsalu Degu, Peter Njogu, Irene Weru and Peter Karimi
    Citation: Gynecologic Oncology Research and Practice 2017 4:15
  17. Preparation in the business of medicine is reported to be poor across a number of specialties. No data exist about such preparation in gynecologic oncology training programs. Our objectives were to evaluate cu...

    Authors: Matthew Schlumbrecht, John Siemon, Guillermo Morales, Marilyn Huang and Brian Slomovitz
    Citation: Gynecologic Oncology Research and Practice 2017 4:14
  18. To determine the cost-effectiveness of transversus abdominis plane block with liposomal bupivacaine (TAP) compared to oral opioids alone for acute postoperative pain after laparoscopic hysterectomy for early e...

    Authors: Brandon-Luke L. Seagle, Emily S. Miller, Anna E. Strohl, Anna Hoekstra and Shohreh Shahabi
    Citation: Gynecologic Oncology Research and Practice 2017 4:12
  19. Due to the significant morbidity and mortality associated with placenta percreta, alternative management options are needed. Beginning in 2005, our institution implemented a multidisciplinary strategy to patie...

    Authors: Paula S. Lee, Samantha Kempner, Michael Miller, Jennifer Dominguez, Chad Grotegut, Jessie Ehrisman, Rebecca Previs, Laura J. Havrilesky, Gloria Broadwater, Sarah C. Ellestad and Angeles Alvarez Secord
    Citation: Gynecologic Oncology Research and Practice 2017 4:11
  20. Survival of patients with advanced, recurrent, or metastatic human papillomavirus (HPV)-associated cancer is suboptimal despite the availability of various treatment modalities. The recently developed bacteria...

    Authors: Brett Miles, Howard P. Safran and Bradley J. Monk
    Citation: Gynecologic Oncology Research and Practice 2017 4:10
  21. Immune responses to the facultative intracellular bacterium Listeria monocytogenes (Lm) are robust and well characterized. Utilized for decades as a model of host-disease immunology, Lm is well suited for use as ...

    Authors: Brett A. Miles, Bradley J. Monk and Howard P. Safran
    Citation: Gynecologic Oncology Research and Practice 2017 4:9
  22. Authors: Dorcas Obiri-Yeboah, Yaw Adu-Sarkodie, Florencia Djigma, Kafui Akakpo, Ebenezer Aniakwa-Bonsu, Daniel Amoako-Sakyi, Jacques Simpore and Philippe Mayaud
    Citation: Gynecologic Oncology Research and Practice 2017 4:8

    The original article was published in Gynecologic Oncology Research and Practice 2017 4:5

  23. Bevacizumab is an important component in the treatment of various cancers, and despite guidelines recommending its use in both ovarian and cervical cancer, patient access to bevacizumab and other angiogenesis ...

    Authors: Bradley J. Monk, Warner K. Huh, Julie Ann Rosenberg and Ira Jacobs
    Citation: Gynecologic Oncology Research and Practice 2017 4:7
  24. Palliative systemic treatment in elderly gynaecological cancer patients remains a major challenge. In recurrent ovarian cancer (ROC), treosulfan an active alkylating drug showed similar cytotoxicity whether as...

    Authors: Radoslav Chekerov, Philipp Harter, Stefan Fuxius, Lars Christian Hanker, Linn Woelber, Lothar Müller, Peter Klare, Wolfgang Abenhardt, Yoana Nedkova, Isil Yalcinkaya, Georg Heinrich, Harald Sommer, Sven Mahner, Pauline Wimberger, Dominique Koensgen-Mustea, Rolf Richter…
    Citation: Gynecologic Oncology Research and Practice 2017 4:6
  25. Modern cervical cancer screening increasingly relies on the use of molecular techniques detecting high-risk oncogenic human papillomavirus (hr-HPV). A major challenge for developing countries like Ghana has be...

    Authors: Dorcas Obiri-Yeboah, Yaw Adu-Sarkodie, Florencia Djigma, Kafui Akakpo, Ebenezer Aniakwa-Bonsu, Daniel Amoako-Sakyi, Jacques Simpore and Philippe Mayaud
    Citation: Gynecologic Oncology Research and Practice 2017 4:5

    The Erratum to this article has been published in Gynecologic Oncology Research and Practice 2017 4:8

  26. Until recently our knowledge of a genetic contribution to ovarian cancer focused almost exclusively on mutations in the BRCA1/2 genes. However, through germline and tumor sequencing an understanding of the larger...

    Authors: Melissa K. Frey and Bhavana Pothuri
    Citation: Gynecologic Oncology Research and Practice 2017 4:4
  27. Nivolumab is an immune checkpoint inhibitor specific for the programmed death 1 (PD-1) receptor that has led to clinical responses in many cancer types. Identifying biomarkers predictive of response to PD-1 bl...

    Authors: Sarah E. Paraghamian, Teresa C. Longoria and Ramez N. Eskander
    Citation: Gynecologic Oncology Research and Practice 2017 4:3
  28. Merkel cell carcinoma is a rare and aggressive neoplasm originating from mechanoreceptor Merkel cells of the stratum basale of the epidermis. Cases affecting the vulva are exceedingly rare, with the currently ...

    Authors: Austin Huy Nguyen, Ahmed I. Tahseen, Adam M. Vaudreuil, Gabriel C. Caponetti and Christopher J. Huerter
    Citation: Gynecologic Oncology Research and Practice 2017 4:2
  29. The National Comprehensive Cancer Network (NCCN) and the Society of Gynecologic Oncology (SGO) recommend lymph node sampling (LNS) as a key component in the surgical staging of high-grade endometrial cancer. O...

    Authors: Jonathan R. Foote, Stephanie Gaillard, Gloria Broadwater, Julie A. Sosa, Brittany Davidson, Mohamed A. Adam, Angeles Alvarez Secord, Monica B. Jones, Junzo Chino and Laura J. Havrilesky
    Citation: Gynecologic Oncology Research and Practice 2017 4:1
  30. Endometrial carcinoma (EC) is the fourth most common cancer in women in the developed world. Classification of ECs by histomorphologic criteria has limited reproducibility and better tools are needed to distin...

    Authors: A. Talhouk and J. N. McAlpine
    Citation: Gynecologic Oncology Research and Practice 2016 3:14
  31. Genetic testing for an inherited susceptibility to cancer is an emerging technology in medical practice. Little information is currently available about physicians’ attitudes towards these tests in developing ...

    Authors: Hanoon P Pokharel, Neville F Hacker and Lesley Andrews
    Citation: Gynecologic Oncology Research and Practice 2016 3:12
  32. Chemotherapy plays a role in the treatment of endometrioid endometrial cancer (EEC); however, tumor grade may affect response. Our objective was to evaluate associations between tumor grade and in vitro chemor...

    Authors: Brittany A. Davidson, Jonathan Foote, Stacey L. Brower, Chunqiao Tian, Laura J. Havrilesky and Angeles Alvarez Secord
    Citation: Gynecologic Oncology Research and Practice 2016 3:13
  33. The Fifth Annual Advanced Course in Cytoreductive Surgery for Ovarian Cancer and Peritoneal Surface Malignancies was held at and sponsored by the Division of Gynecologic Oncology at the the University of Calif...

    Authors: Krishnansu S. Tewari
    Citation: Gynecologic Oncology Research and Practice 2016 3:10
  34. Cervical cancer is the fourth most common cancer among women worldwide, many of who are still within their reproductive lifespan. Advances in screening and treatment have increased the 5-year survival for earl...

    Authors: Karla Willows, Genevieve Lennox and Allan Covens
    Citation: Gynecologic Oncology Research and Practice 2016 3:9
  35. Our objective was to determine if previously reported overall survival (OS) and progression-free survival (PFS) rates are maintained long term following multimodal therapy for advanced and recurrent endometria...

    Authors: Michelle Glasgow, Rachel Isaksson Vogel, Jennifer Burgart, Peter Argenta, Kathryn Dusenbery and Melissa A. Geller
    Citation: Gynecologic Oncology Research and Practice 2016 3:6
  36. Selumetinib is a potent, selective, orally available, and non-ATP competitive small molecule inhibitor of mitogen-activated protein kinase kinase 1/2 (MEK1/2) that has demonstrated single agent activity in a n...

    Authors: Munetaka Takekuma, Kwong K. Wong and Robert L. Coleman
    Citation: Gynecologic Oncology Research and Practice 2016 3:5
  37. After platinum and taxane chemotherapy, with or without bevacizumab, active regimens for advanced or recurrent cervical cancer are lacking. Our objective was to review a single institution experience in treati...

    Authors: Lindsey E. Minion, Dana M. Chase, John H. Farley, Lyndsay J. Willmott and Bradley J. Monk
    Citation: Gynecologic Oncology Research and Practice 2016 3:4
  38. Poly(ADP-ribose) polymerase (PARP), which was first described over 50 years ago by Mandel, are a family of protein enzymes involved in DNA damage response and works by recognizing the single-strand DNA break (...

    Authors: Robert S. Meehan and Alice P. Chen
    Citation: Gynecologic Oncology Research and Practice 2016 3:3
  39. Many women who develop endometrial cancer (EC) or endometrial hyperplasia with atypia are obese and therefore at high risk of surgical complications. Recently clinical trials have been initiated offering non-s...

    Authors: Andreas Obermair, Donal J. Brennan, Eva Baxter, Jane E. Armes, Val Gebski and Monika Janda
    Citation: Gynecologic Oncology Research and Practice 2016 3:1
  40. Radiation induced Lumbosacral plexophaty (RILP) is a rare but severe complication that has a considerable impact on quality of life. Its occurrence is rare but increasing with improved long-term cancer surviva...

    Authors: Imane Bourhafour, Meriem Benoulaid, Hanane El Kacemi, Sanae El Majjaoui, Tayeb Kebdani and Noureddine Benjaafar
    Citation: Gynecologic Oncology Research and Practice 2015 2:12
  41. Endometrial cancer is the only gynecologic malignancy with a rising incidence and mortality. While cure is routinely achieved with surgery alone or in combination with adjuvant pelvic radiotherapy when disease...

    Authors: Teresa C. Longoria and Ramez N. Eskander
    Citation: Gynecologic Oncology Research and Practice 2015 2:11

    The Erratum to this article has been published in Gynecologic Oncology Research and Practice 2016 3:2

  42. Early-stage vaginal and vulvar cancer can be cured. But outcomes of patients with metastatic disease are poor. Thus, new therapeutic strategies are urgently required.

    Authors: Siqing Fu, Naiyi Shi, Jennifer Wheler, Aung Naing, Filip Janku, Sarina Piha-Paul, Jing Gong, David Hong, Apostolia Tsimberidou, Ralph Zinner, Vivek Subbiah, Ming-Mo Hou, Pedro Ramirez, Lois Ramondetta, Karen Lu and Funda Meric-Bernstam
    Citation: Gynecologic Oncology Research and Practice 2015 2:10
  43. The incidence of molar pregnancy has demonstrated marked geographic and ethnic differences. The reported data in Nepal is inconsistent with minimal published literature. Thus, we designed a study to determine ...

    Authors: Nimisha Agrawal, Reshu Agrawal Sagtani, Shyam Sundar Budhathoki and Hanoon P. Pokharel
    Citation: Gynecologic Oncology Research and Practice 2015 2:9
  44. Despite the introduction of screening and, latterly, vaccination programs in the developed world, globally cervical cancer remains a significant health problem. For those diagnosed with advanced or recurrent d...

    Authors: Victor Rodriguez-Freixinos and Helen J. Mackay
    Citation: Gynecologic Oncology Research and Practice 2015 2:8
  45. Cervical cancer (CC) is one of the most widespread gynecological malignancies in women worldwide. Treatment strategies and screening modalities have largely evolved these past years resulting in an improvement...

    Authors: J. Khalil, S. Bellefqih, N. Sahli, M. Afif, H. Elkacemi, S. Elmajjaoui, T. Kebdani and N. Benjaafar
    Citation: Gynecologic Oncology Research and Practice 2015 2:7